BACKGROUND: Angiopoetin- (Ang-) 1 inhibits and Ang-2 promotes VEGF-mediated angiogenesis via binding to endothelial cell-bound Tie-2 receptor (Tie-2). After minimally invasive colorectal resection (MICR), Ang-1 levels decrease and Ang-2 levels increase, which may stimulate angiogenesis in wounds and residual tumor foci. Soluble Tie-2 (sTie-2) modulates the effects of free Ang-1 and Ang-2 by binding to them. This study assessed perioperative MICR plasma sTie-2 levels. METHODS: Blood samples were taken preoperatively (PreOp) and on postoperative days (POD) 1 and 3 from 50 cancer and 53 benign disease MICR patients. In a subgroup, a fourth sample was taken between POD7 and POD13 and bundled as a single time point. sTie-2 levels (ng/ml) were determined via ELISA. The mean and SD were determined at each time point. The t test used for analysis. RESULTS: PreOp plasma sTie-2 levels were significantly higher in the benign group (27.6 ± 10.2) than in the cancer group (22.9 ± 7.9). A significant drop from PreOp occurred in sTie-2 levels in the cancer group on POD1 (20.0 ± 7.4) and POD3 (21.0 ± 6.6) and in the benign group on POD1 (24.8 ± 9.1). The benign group's POD3 and the cancer group's POD7-13 sTie-2 levels were statistically similar to the PreOp levels while the benign group's POD7-13 level was significantly higher. CONCLUSION: PreOp sTie-2 levels were significantly lower in cancer patients. MICR is associated with a significant short-lived decrease in plasma sTie-2 levels in cancer patients on POD1 and 3, which may briefly inhibit VEGF-mediated angiogenesis. The benign group's early results were similar.
BACKGROUND:Angiopoetin- (Ang-) 1 inhibits and Ang-2 promotes VEGF-mediated angiogenesis via binding to endothelial cell-bound Tie-2 receptor (Tie-2). After minimally invasive colorectal resection (MICR), Ang-1 levels decrease and Ang-2 levels increase, which may stimulate angiogenesis in wounds and residual tumor foci. Soluble Tie-2 (sTie-2) modulates the effects of free Ang-1 and Ang-2 by binding to them. This study assessed perioperative MICR plasma sTie-2 levels. METHODS: Blood samples were taken preoperatively (PreOp) and on postoperative days (POD) 1 and 3 from 50 cancer and 53 benign disease MICR patients. In a subgroup, a fourth sample was taken between POD7 and POD13 and bundled as a single time point. sTie-2 levels (ng/ml) were determined via ELISA. The mean and SD were determined at each time point. The t test used for analysis. RESULTS: PreOp plasma sTie-2 levels were significantly higher in the benign group (27.6 ± 10.2) than in the cancer group (22.9 ± 7.9). A significant drop from PreOp occurred in sTie-2 levels in the cancer group on POD1 (20.0 ± 7.4) and POD3 (21.0 ± 6.6) and in the benign group on POD1 (24.8 ± 9.1). The benign group's POD3 and the cancer group's POD7-13 sTie-2 levels were statistically similar to the PreOp levels while the benign group's POD7-13 level was significantly higher. CONCLUSION: PreOp sTie-2 levels were significantly lower in cancerpatients. MICR is associated with a significant short-lived decrease in plasma sTie-2 levels in cancerpatients on POD1 and 3, which may briefly inhibit VEGF-mediated angiogenesis. The benign group's early results were similar.
Authors: A K Mels; M G Statius Muller; P A van Leeuwen; B M von Blomberg; R J Scheper; M A Cuesta; R H Beelen; S Meijer Journal: Br J Surg Date: 2001-04 Impact factor: 6.939
Authors: A J Leather; N C Gallegos; G Kocjan; F Savage; C S Smales; W Hu; P B Boulos; J M Northover; R K Phillips Journal: Br J Surg Date: 1993-06 Impact factor: 6.939
Authors: A Belizon; E Balik; P Horst; D Feingold; T Arnell; T Azarani; V Cekic; R Skitt; S Kumara; R L Whelan Journal: Surg Endosc Date: 2008-01-18 Impact factor: 4.584
Authors: H M C Shantha Kumara; I Kirman; D Feingold; V Cekic; A Nasar; T Arnell; E Balik; A Hoffman; R Baxter; S Conte; R L Whelan Journal: Eur J Surg Oncol Date: 2008-09-07 Impact factor: 4.424
Authors: Aun Yeong Chong; Graham J Caine; Bethan Freestone; Andrew D Blann; Gregory Y H Lip Journal: J Am Coll Cardiol Date: 2004-02-04 Impact factor: 24.094
Authors: H M C Shantha Kumara; H M C Shantha Kumara; Daniel Feingold; Matthew Kalady; Nadav Dujovny; Anthony Senagore; Neil Hyman; Vesna Cekic; Richard L Whelan Journal: Ann Surg Date: 2009-06 Impact factor: 12.969
Authors: I Kirman; A Belizon; E Balik; D Feingold; T Arnell; P Horst; S Kumara; V Cekic; S Jain; A Nasar; R L Whelan Journal: Eur J Surg Oncol Date: 2007-05-18 Impact factor: 4.424
Authors: Ewa Kopczyńska; Maciej Dancewicz; Janusz Kowalewski; Roman Makarewicz; Hanna Kardymowicz; Agnieszka Kaczmarczyk; Tomasz Tyrakowski Journal: ISRN Oncol Date: 2012-03-26